{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:24:08Z","timestamp":1787034248304,"version":"build-2736575974"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,17]]},"DOI":"10.7759\/cureus.114699","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:25:23Z","timestamp":1787030723000},"source":"Crossref","is-referenced-by-count":0,"title":["Cardiometabolic Response to Saroglitazar in a Young Indian Man With Obesity, Prediabetes, Insulin Resistance, and High-Normal Albuminuria: A Case Report"],"prefix":"10.7759","author":[{"given":"Supratik","family":"Bhattacharyya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00119-5","article-title":"Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17)","volume":"11","author":"Anjana RM","year":"2023","unstructured":"Anjana RM, Unnikrishnan R, Deepa M, et al.. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023, 11:474-89. 10.1016\/S2213-8587(23)00119-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref2","article-title":"Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management","volume":"57","author":"Misra A","year":"2009","unstructured":"Misra A, Chowbey P, Makkar BM, et al.. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India. 2009, 57:163-70.","journal-title":"J Assoc Physicians India"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2013.0253","article-title":"A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4\u2009mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI)","volume":"16","author":"Jani RH","year":"2014","unstructured":"Jani RH, Pai V, Jha P, Jariwala G, Mukhopadhyay S, Bhansali A, Joshi S. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4\u2009mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes Technol Ther. 2014, 16:63-71. 10.1089\/dia.2013.0253","journal-title":"Diabetes Technol Ther"},{"key":"ref4","article-title":"Study of Saroglitazar in Treatment Of Pre-diabetes with Dyslipidemia: STOP-D","volume":"66","author":"Bhosle D","year":"2018","unstructured":"Bhosle D, Bhosle V, Bobde J, Bhagat A, Shaikh H, Kadam R. Study of Saroglitazar in Treatment Of Pre-diabetes with Dyslipidemia: STOP-D. J Assoc Physicians India. 2018, 66:14-7.","journal-title":"J Assoc Physicians India"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S002","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes-2026","volume":"49","year":"2026","unstructured":"2. Diagnosis and classification of diabetes. standards of care in diabetes-2026. Diabetes Care. 2026, 49:S27-49. 10.2337\/dc26-S002","journal-title":"Diabetes Care"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews DR","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985, 28:412-9. 10.1007\/BF00280883","journal-title":"Diabetologia"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","year":"2024","unstructured":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024, 105.S117-314. 10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs290","article-title":"Role of insulin resistance in kidney dysfunction: insights into the mechanism and epidemiological evidence","volume":"28","author":"De Cosmo S","year":"2013","unstructured":"De Cosmo S, Menzaghi C, Prudente S, Trischitta V. Role of insulin resistance in kidney dysfunction: insights into the mechanism and epidemiological evidence. Nephrol Dial Transplant. 2013, 28:29-36. 10.1093\/ndt\/gfs290","journal-title":"Nephrol Dial Transplant"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2297","article-title":"Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis","volume":"370","author":"Cai X","year":"2020","unstructured":"Cai X, Zhang Y, Li M, et al.. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ. 2020, 370:m2297. 10.1136\/bmj.m2297","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0884-3","article-title":"New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence","volume":"18","author":"Kaul U","year":"2019","unstructured":"Kaul U, Parmar D, Manjunath K, Shah M, Parmar K, Patil KP, Jaiswal A. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence. Cardiovasc Diabetol. 2019, 18:80. 10.1186\/s12933-019-0884-3","journal-title":"Cardiovasc Diabetol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/521219-cardiometabolic-response-to-saroglitazar-in-a-young-indian-man-with-obesity-prediabetes-insulin-resistance-and-high-normal-albuminuria-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:25:24Z","timestamp":1787030724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/521219-cardiometabolic-response-to-saroglitazar-in-a-young-indian-man-with-obesity-prediabetes-insulin-resistance-and-high-normal-albuminuria-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.114699","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,17]]}}}